Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients. (PRECI-Surg)
Primary Purpose
Diabetes Mellitus Type 2 in Obese
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Standard Roux-en-Y gastric bypass
Long alimentary limb Roux-en-Y gastric bypass
Sponsored by
About this trial
This is an interventional treatment trial for Diabetes Mellitus Type 2 in Obese focused on measuring Obesity, Diabetes Mellitus Type 2, Bariatric Surgery, Roux-en-Y, gastric bypass
Eligibility Criteria
Inclusion Criteria:
- BMI ≥ 35 kg/m2
- All patient with type 2 diabetes
- Patients who were candidates for obesity surgery in accordance with French recommendation
Exclusion Criteria:
- Severe cognitive or mental disorders
- patient who have already undergone obesity surgery
- Severe and non-stabilised eating disorders
- The likely inability of the patient to participate in lifelong medical follow-up
- Alcohol or psychoactive substances dependence
- The absence of identified prior medical management of obesity
- Diseases that are life-threatening in the short and medium term;
- Contraindications to general anaesthesia.
Sites / Locations
- Chu Amiens PicardieRecruiting
- Ch Boulogne-Sur-MeRecruiting
- Hop Claude Huriez Chu LilleRecruiting
- Ch de ValenciennesRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Sham Comparator
Active Comparator
Arm Label
Standard Roux-en-Y
Long alimentary limb Roux-en-Y
Arm Description
Outcomes
Primary Outcome Measures
Rate of type 2 diabetes remission
HbA1c < 6.5% AND fasting blood glucose < 7.0 mmol/L in absence of antidiabetic drug
Secondary Outcome Measures
Absolute weight loss (aWL in kg)
Excess Weight Loss percentage (EWL%)
Excess BMI Loss percentage (EBL%)
Medical and surgical complication rates
Medical and surgical complication rates (anastomotic leaks, biliary reflux, bowel obstruction, anastomotic ulcers, anastomotic stenosis, internal hernia, chronic gastritis, esophagitis, iron deficiency anemia)
Type and severity of early and late complications for each procedure
Type and severity of early and late complications for each procedure, according to the Dindo-Clavien classification
Patient's quality of life score according to the Impact of Weight on Quality of Life (IWQOL) questionnaire
The IWQOL questionnaire to be specifically assess the effects of obesity on health-related quality of life. The five identified scales are Physical Function, Self-Esteem, Sexual Life, Public Distress, and Work.
The final 20-item IWQOL includes two primary domains: Physical (7 items) and Psychosocial (13 items)
Patient's quality of life score according to the Gastrointestinal Quality of Life Index (GIQLI) questionnaire adapted to bariatric surgery.
GIQLI (gastrointestinal quality of life index) questionnaire. 36 questions, each containing 4 answers equating to a score ranging from 0 (least desirable answer) to 4 (most desirable answer). Total score range 0-144.
Change in glucose homeostasis
glucose (mg/dl)
Change in HbA1c
Changes in HbA1c(%) were assessed before and after surgery
Change in fasting glycemia
Changes in fasting blood glucose levels (mmol/L)
changes in fasting insulinemia
Changes in fasting insulinemia in microunits/mL
change in fasting c-peptide
Changes in C-peptide(ng/ml) were assessed before and after the intervention.
Number of antidiabetic treatments
Metabolic profile of glucose homeostasis assessment according to antidiabetic treatments, HbA1c level, fasting glycemia, fasting insulinemia fasting c-peptide
Changes in blood lipids profile
Changes in blood lipids profile (LDL, HDL and triglyceride concentrations) according to anitilipidemic treatments
change in vitamins status assessment
vitamines profil (vitamin B1, B9, B12, and D concentration) before and 12 and 24 months after surgery
change in prealbumin levels
Lower levels of prealbumin are associated with malnutrition.
Full Information
NCT ID
NCT03821636
First Posted
November 26, 2018
Last Updated
February 6, 2023
Sponsor
University Hospital, Lille
Collaborators
Ministry of Health, France
1. Study Identification
Unique Protocol Identification Number
NCT03821636
Brief Title
Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients.
Acronym
PRECI-Surg
Official Title
Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients. A Prospective, Multicentric, Randomized, Controlled Trial.
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 16, 2019 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Lille
Collaborators
Ministry of Health, France
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In patients with type 2 diabetes, Roux-en-Y gastric bypass (RYGB), which excludes a portion of the stomach and the proximal intestine from the alimentary circuit, improves glucose metabolism more rapidly and more extensively than is expected from weight loss. The mechanisms of this unique effect of gastrointestinal exclusion appear to be complex and have not yet been clarified. A recent study unveil that intestinal uptake of ingested glucose is diminished by RYGB and restricted to the common limb, where food meets bile and other digestive fluids, resulting in an overall decrease of post prandial blood glucose excursion. the hypothesize that reducing the length of the common limb, which is rarely measured and highly variable in clinical practice, may significantly affect the metabolic outcome of gastrointestinal surgical procedures. The aim of the present study is to compare the impact of two variants of Roux-en-Y gastric bypass with a short common limb, the long alimentary limb or the long biliary limb Roux-en-Y gastric bypass, on type 2 diabetes remission in severely obese patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 2 in Obese
Keywords
Obesity, Diabetes Mellitus Type 2, Bariatric Surgery, Roux-en-Y, gastric bypass
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
396 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Standard Roux-en-Y
Arm Type
Sham Comparator
Arm Title
Long alimentary limb Roux-en-Y
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Standard Roux-en-Y gastric bypass
Intervention Description
Standard Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 25 % of total length of the intestine (150 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 65 % of total length of the intestine (400 cm).
Intervention Type
Procedure
Intervention Name(s)
Long alimentary limb Roux-en-Y gastric bypass
Intervention Description
Long alimentary limb Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 45 % of total length of the intestine (280 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 45 % of total length of the intestine (280 cm
Primary Outcome Measure Information:
Title
Rate of type 2 diabetes remission
Description
HbA1c < 6.5% AND fasting blood glucose < 7.0 mmol/L in absence of antidiabetic drug
Time Frame
at 12 months after surgery
Secondary Outcome Measure Information:
Title
Absolute weight loss (aWL in kg)
Time Frame
at 1, 3, 6 and 12 months after surgery
Title
Excess Weight Loss percentage (EWL%)
Time Frame
at 1, 3, 6 and 12 months after surgery
Title
Excess BMI Loss percentage (EBL%)
Time Frame
at 1, 3, 6 and 12 months after surgery
Title
Medical and surgical complication rates
Description
Medical and surgical complication rates (anastomotic leaks, biliary reflux, bowel obstruction, anastomotic ulcers, anastomotic stenosis, internal hernia, chronic gastritis, esophagitis, iron deficiency anemia)
Time Frame
During the month following surgery (for early complications) and from one month to 12 months postoperatively (for late complications)]
Title
Type and severity of early and late complications for each procedure
Description
Type and severity of early and late complications for each procedure, according to the Dindo-Clavien classification
Time Frame
During the month following surgery (for early complications) and from one month to 12 months postoperatively (for late complications)]
Title
Patient's quality of life score according to the Impact of Weight on Quality of Life (IWQOL) questionnaire
Description
The IWQOL questionnaire to be specifically assess the effects of obesity on health-related quality of life. The five identified scales are Physical Function, Self-Esteem, Sexual Life, Public Distress, and Work.
The final 20-item IWQOL includes two primary domains: Physical (7 items) and Psychosocial (13 items)
Time Frame
Before surgery and at 12 after surgery
Title
Patient's quality of life score according to the Gastrointestinal Quality of Life Index (GIQLI) questionnaire adapted to bariatric surgery.
Description
GIQLI (gastrointestinal quality of life index) questionnaire. 36 questions, each containing 4 answers equating to a score ranging from 0 (least desirable answer) to 4 (most desirable answer). Total score range 0-144.
Time Frame
Before surgery and at 12 after surgery
Title
Change in glucose homeostasis
Description
glucose (mg/dl)
Time Frame
Before surgery and at 3, 6 and 12 months after surgery
Title
Change in HbA1c
Description
Changes in HbA1c(%) were assessed before and after surgery
Time Frame
Before surgery and at 3, 6 and 12 months after surgery
Title
Change in fasting glycemia
Description
Changes in fasting blood glucose levels (mmol/L)
Time Frame
Before surgery and at 3, 6 and 12 months after surgery
Title
changes in fasting insulinemia
Description
Changes in fasting insulinemia in microunits/mL
Time Frame
Before surgery and at 3, 6 and 12 months after surgery
Title
change in fasting c-peptide
Description
Changes in C-peptide(ng/ml) were assessed before and after the intervention.
Time Frame
Before surgery and at 3, 6 and 12 months after surgery
Title
Number of antidiabetic treatments
Description
Metabolic profile of glucose homeostasis assessment according to antidiabetic treatments, HbA1c level, fasting glycemia, fasting insulinemia fasting c-peptide
Time Frame
Before surgery and at 3, 6 and 12 months after surgery
Title
Changes in blood lipids profile
Description
Changes in blood lipids profile (LDL, HDL and triglyceride concentrations) according to anitilipidemic treatments
Time Frame
Before surgery and at 1, 3, 6 and 12 months after surgery
Title
change in vitamins status assessment
Description
vitamines profil (vitamin B1, B9, B12, and D concentration) before and 12 and 24 months after surgery
Time Frame
Before surgery and at 1, 3, 6 and 12 months after surgery
Title
change in prealbumin levels
Description
Lower levels of prealbumin are associated with malnutrition.
Time Frame
Before surgery and at 1, 3, 6 and 12 months after surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
BMI ≥ 35 kg/m2
All patient with type 2 diabetes
Patients who were candidates for obesity surgery in accordance with French recommendation
Exclusion Criteria:
Severe cognitive or mental disorders
patient who have already undergone obesity surgery
Severe and non-stabilised eating disorders
The likely inability of the patient to participate in lifelong medical follow-up
Alcohol or psychoactive substances dependence
The absence of identified prior medical management of obesity
Diseases that are life-threatening in the short and medium term;
Contraindications to general anaesthesia.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Grégory BAUD, MD
Phone
3.20.44.42.73
Ext
+33
Email
gregory.baud@chru-lille.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Grégory BAUD, MD
Organizational Affiliation
University Hospital, Lille
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chu Amiens Picardie
City
Amiens
Country
France
Individual Site Status
Recruiting
Facility Name
Ch Boulogne-Sur-Me
City
Boulogne Sur Mer
ZIP/Postal Code
62321
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
0321993333
Facility Name
Hop Claude Huriez Chu Lille
City
Lille
ZIP/Postal Code
59037
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
0320445962
Facility Name
Ch de Valenciennes
City
Valenciennes
Country
France
Individual Site Status
Recruiting
12. IPD Sharing Statement
Learn more about this trial
Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients.
We'll reach out to this number within 24 hrs